🇺🇸 FDA
Patent

US 11633501

Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof

granted A61KA61K2039/505A61K47/68033

Quick answer

US patent 11633501 (Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61K47/68033, A61K47/6869, A61K47/6871